Colorectal cancer ranks as the third most prevalent cancer affecting the population in the United States, presenting a significant public health challenge. Over the past two decades, widespread screening programs have contributed to a notable decline in the overall incidence of colorectal cancer. However, a troubling countertrend has emerged: the incidence of early-onset colorectal cancer among younger patients is on the rise. Despite advancements in surgical techniques and adjuvant therapies, metastatic colorectal cancer outcomes remain poor, necessitating the exploration of novel therapeutic avenues.
Recent research conducted by scientists at the University of Michigan has illuminated a critical molecular pathway driving colorectal cancer progression—specifically implicating sustained activation of the signal transducer and activator of transcription 3 (STAT3) protein. Aberrant STAT3 signaling is frequently observed in colorectal cancer cells and is known to promote tumorigenesis by regulating genes involved in cell proliferation, survival, and immune evasion. This study, published in the esteemed journal Science Signaling, reveals a compelling connection between glucose metabolism and sustained STAT3 activation within colorectal cancer cells.
The investigative team embarked on experimental studies utilizing various colorectal cancer cell lines to dissect the molecular underpinnings of STAT3 hyperactivation. Their findings demonstrate that physiological blood glucose concentrations are sufficient to maintain elevated STAT3 signaling, whereas deprivation of glucose markedly attenuates its activation. This discovery underscores a previously underappreciated mechanism by which glucose metabolism fuels oncogenic signaling pathways.
Professor Yatrik Shah, an authority in molecular and integrative physiology and a Rogel Cancer Center member, emphasized the significance of these observations. He noted that while the pro-tumorigenic role of glucose and other sugars has been recognized for some time, the specific pathway through which these metabolites exert their effects was unclear until now. Their results elucidate that glucose facilitates tumor growth by promoting persistent activation of the STAT3 pathway, a driver of malignant transformation.
Further expanding the scope of their inquiry, the researchers extended their analysis to pancreatic, liver, and cervical cancer cell lines, where they observed analogous glucose-mediated STAT3 activation. This broadens the implications of their findings, suggesting that glucose-dependent modulation of STAT3 may represent a conserved oncogenic mechanism across multiple cancer types.
The researchers delved deeper into the biochemical basis of this effect and discovered that glycosylated proteins—proteins modified through the enzymatic attachment of sugar moieties—play a pivotal role in mediating the glucose-stimulated STAT3 signaling axis. Although the specific identities of these glycosylated signaling factors remain to be elucidated, it is evident they are secreted by colorectal cancer cells into the extracellular milieu. This secretion facilitates paracrine and autocrine activation of STAT3, perpetuating oncogenic signaling not only within the originating cells but also neighboring tumor cells.
These findings open an intriguing therapeutic avenue: targeting glucose metabolism or the associated glycosylation processes could diminish the pathological activation of STAT3, potentially curbing tumor growth and improving patient outcomes. Currently, the researchers are focused on pinpointing the exact glycosylated proteins involved in this signaling cascade, aiming to develop strategies that selectively inhibit their function.
Graduate student Kathryn Buscher, first author of the publication, highlighted the broader relevance of STAT3 signaling beyond oncology. Given the pathway’s involvement in conditions such as non-alcoholic fatty liver disease and inflammatory bowel disease, the newly unearthed glucose-dependent regulatory mechanism may have significant ramifications for a spectrum of diseases characterized by chronic inflammation and dysregulated cellular signaling.
These mechanistic insights are particularly timely, considering ongoing efforts to decipher the metabolic dependencies of cancer cells. The interplay between cellular metabolism and signaling pathways forms a complex network that fuels malignant phenotypes, and interventions designed to disrupt this crosstalk hold promise. Dr. Shah’s team’s work advances this frontier by demonstrating a direct causal link between glucose metabolism and persistent STAT3 activation.
From a translational standpoint, this research encourages a reexamination of metabolic interventions—such as dietary modulation, glucose-lowering pharmacotherapies, or inhibitors of protein glycosylation—as complementary adjuncts to existing colorectal cancer treatments. By attenuating STAT3 signaling through metabolic targeting, it might be feasible to overcome therapeutic resistance and limit metastatic progression.
Moreover, the study’s revelation that glucose-sustained glycosylated factors operate in a paracrine fashion invites further exploration into the tumor microenvironment’s role in colorectal cancer biology. Understanding the extracellular signaling milieu and its interplay with cancer metabolism could unveil novel biomarkers and drug targets, facilitating personalized therapeutic approaches.
This research was supported by numerous grants from the National Institutes of Health, the Department of Defense, and institutional sources, reflecting a collaborative effort integrating expertise across disciplines. Disclosures note that one of the co-authors, Costas A. Lyssiotis, holds consultancy positions with pharmaceutical companies and possesses patents related to cancer metabolism pathways, underscoring the translational potential of metabolic research.
In conclusion, the University of Michigan team’s discovery that glucose metabolism sustains aberrant STAT3 signaling through glycosylated local factors presents a seminal advance in understanding colorectal cancer biology. By delineating the molecular crosstalk between metabolism and oncogenic signaling, their work sets the stage for innovative therapeutic strategies aimed at dismantling the metabolic scaffolds of tumor growth. As further investigations clarify the precise molecular players and their mechanisms, this paradigm promises to reshape interventions not just for colorectal cancer but potentially for a broad array of diseases driven by pathological STAT3 activation.
Subject of Research: Cells
Article Title: Glucose Metabolism Sustains Aberrant STAT3 Signaling in Colorectal Cancer via Glycosylated Local Signaling Factors
News Publication Date: 3-Mar-2026
Web References:
https://doi.org/10.1126/scisignal.adz6443
References:
“Glucose Metabolism Sustains Aberrant STAT3 Signaling in Colorectal Cancer via Glycosylated Local Signaling Factors,” Science Signaling.
Keywords: Colorectal cancer, STAT3 signaling, glucose metabolism, glycosylated proteins, cancer metabolism, tumor microenvironment, oncogenic signaling, molecular physiology, therapeutic targets
